1887
  1. Home
  2. Eurosurveillance
  3. Volume 27, Issue 18, 05/May/2022
  4. Article
Rapid communication Open Access
Like 0
Download

Abstract

We compared vaccine effectiveness against severe COVID-19 between December 2021 and March 2022 when Omicron BA.1 and BA.2 were the dominating SARS-CoV-2 variants in Scania county, Sweden. Effectiveness remained above 80% after the transition from BA.1 to BA.2 among people with at least three vaccine doses but the point estimate decreased markedly to 54% among those with only two doses. Protection from prior infection was also lower after the transition to BA.2. Booster vaccination seems necessary to maintain sufficient protection.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2022.27.18.2200322
2022-05-05
2024-12-22
/content/10.2807/1560-7917.ES.2022.27.18.2200322
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/27/18/eurosurv-27-18-2.html?itemId=/content/10.2807/1560-7917.ES.2022.27.18.2200322&mimeType=html&fmt=ahah

References

  1. Lyngse FP, Kirkeby CT, Denwood M, Christiansen LE, Mølbak K, Møller CH, et al. Transmission of SARS-CoV-2 Omicron VOC subvariants BA.1 and BA.2: Evidence from Danish households. medRxiv. 2022.01.28.22270044. Preprint.  https://doi.org/10.1101/2022.01.28.22270044 
  2. Kirsebom FCM, Andrews N, Stowe J, Toffa S, Sachdeva R, Gallagher E, et al. COVID-19 Vaccine Effectiveness against the Omicron BA.2 variant in England. medRxiv. 2022.03.22.22272691. Preprint.  https://doi.org/10.1101/2022.03.22.22272691 
  3. Altarawneh HN, Chemaitelly H, Ayoub HH, Tang P, Hasan MR, Yassine HM, et al. Effect of prior infection, vaccination, and hybrid immunity against symptomatic BA.1 and BA.2 Omicron infections and severe COVID-19 in Qatar. medRxiv. 2022.03.22.22272745. Preprint.  https://doi.org/10.1101/2022.03.22.22272745 
  4. Björk J, Inghammar M, Moghaddassi M, Rasmussen M, Malmqvist U, Kahn F. High level of protection against COVID-19 after two doses of BNT162b2 vaccine in the working age population - first results from a cohort study in Southern Sweden. Infect Dis (Lond). 2022;54(2):128-33.  https://doi.org/10.1080/23744235.2021.1982144  PMID: 34586934 
  5. Kahn F, Bonander C, Moghaddassi M, Rasmussen M, Malmqvist U, Inghammar M, et al. Risk of severe COVID-19 from the Delta and Omicron variants in relation to vaccination status, sex, age and comorbidities - surveillance results from southern Sweden, July 2021 to January 2022. Euro Surveill. 2022;27(9):2200121.  https://doi.org/10.2807/1560-7917.ES.2022.27.9.2200121  PMID: 35241215 
  6. Dean NE. Re: "Measurement of vaccine direct effects under the test-negative design". Am J Epidemiol. 2019;188(4):806-10.  https://doi.org/10.1093/aje/kwz019  PMID: 30689690 
  7. Inghammar M, Moghaddassi M, Rasmussen M, Malmqvist U, Kahn F, Björk J. COVID-19 vaccine uptake among older people in relation to sociodemographic factors –cohort results from southern Sweden. medRxiv. 2021.08.12.21261981. Preprint.  https://doi.org/10.1101/2021.08.12.21261981 
  8. Eales O, de Oliveira Martins L, Page AJ, Wang H, Bodinier B, Tang D, et al. The new normal? Dynamics and scale of the SARS-CoV-2 variant Omicron epidemic in England. medRxiv. 2022.03.29.22273042. Preprint.  https://doi.org/10.1101/2022.03.29.22273042 
  9. Nordström P, Ballin M, Nordström A. Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden. Lancet Infect Dis. 2022;S1473-3099(22)00143-8. PMID: 35366962 
  10. Chemaitelly H, Ayoub HH, Coyle P, Tang P, Yassine HM, Al-Khatib HA, et al. Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage. medRxiv. 2022.02.24.22271440. Preprint.  https://doi.org/10.1101/2022.02.24.22271440 
COVID-19 vaccine effectiveness against severe disease from SARS-CoV-2 Omicron BA.1 and BA.2 subvariants – surveillance results from southern Sweden, December 2021 to March 2022
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Jonas+Bj%C3%B6rk&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Björk Jonas</a>, <a href="/search?value1=Carl+Bonander&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Bonander Carl</a>, <a href="/search?value1=Mahnaz+Moghaddassi&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Moghaddassi Mahnaz</a>, <a href="/search?value1=Magnus+Rasmussen&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Rasmussen Magnus</a>, <a href="/search?value1=Ulf+Malmqvist&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Malmqvist Ulf</a>, <a href="/search?value1=Malin+Inghammar&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Inghammar Malin</a>, <a href="/search?value1=Fredrik+Kahn&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Kahn Fredrik</a></span>. COVID-19 vaccine effectiveness against severe disease from SARS-CoV-2 Omicron BA.1 and BA.2 subvariants – surveillance results from southern Sweden, December 2021 to March 2022. <a href="/content/ecdc">Euro Surveill.</a> 2022;27(18):pii=2200322. <a href="https://doi.org/10.2807/1560-7917.ES.2022.27.18.2200322" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2022.27.18.2200322</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 14 Apr 2022;&nbsp;&nbsp; <span class="generated">Accepted</span>: 05 May 2022 </span> </p>
/content/10.2807/1560-7917.ES.2022.27.18.2200322
/content/10.2807/1560-7917.ES.2022.27.18.2200322
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error